Source link : https://www.newshealth.biz/health-news/sub-q-tocilizumab-gives-durable-long-term-responses-in-jia/
TOPLINE: Subcutaneous tocilizumab provides durable disease control rates in patients with polyarticular and systemic juvenile idiopathic arthritis (pJIA and sJIA, respectively). METHODOLOGY: This long-term extension (LTE) study included 44 patients with pJIA and 38 patients with sJIA, according to the International League of Associations for Rheumatology criteria, from two 52-week phase 1b trials (NCT01904292 and […]
Author : News Health
Publish date : 2024-04-12 07:58:50
Copyright for syndicated content belongs to the linked Source.